- Effects probably mediated by antagonism of dopamine type 2 (D2) and serotonin type 2 (5-HT2). Also antagonizes
2 adrenergic receptors.
- Diminished schizophrenic behavior.
- Reduced symptoms of mania.
Contraindicated in:
Use Cautiously in:
CV: QT interval prolongation, orthostatic hypotension.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), rash, STEVENS-JOHNSON SYNDROME (SJS), urticaria.
EENT: rhinorrhea.
Endo: galactorrhea, hyperglycemia.
GI: constipation, diarrhea, nausea, dysphagia.
GU: amenorrhea, impotence.
Hemat: AGRANULOCYTOSIS, leukopenia, neutropenia.
Metab: hyperlipidemia, weight gain.
Neuro: dizziness, drowsiness, restlessness, extrapyramidal reactions, NEUROLEPTIC MALIGNANT SYNDROME, seizures, syncope, tardive dyskinesia.
Resp: cough.
Drug-Drug:
(Generic available)
Schizophrenia
Acute Manic or Mixed Episodes Associated with Bipolar I Disorder
Maintenance Treatment of Bipolar I Disorder (as adjunct to lithium or valproate)
2 adrenergic receptors.Absorption: 60% absorbed following oral administration; 100% absorbed from IM sites.
Distribution: Well distributed to tissues.
Protein Binding: 99%.
Metabolism/Excretion: 99% metabolized by the liver; <1% excreted unchanged in urine.
Half-life: PO: 7 hr; IM: 2–5 hr.
(plasma concentrations)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within hrs | 1–3 days† | unknown |
| IM | rapid | 60 min | unknown |
†Steady state achieved following continuous use.
NDC Code*
